UBA 22.10 Urstadt Biddle Properties Inc $UBA Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
UBA 22.10 Urstadt Biddle Properties Inc $UBA Hit a 52 week high of 22.18 Currently at 22.10 -0.15 -0.67% With a day low of 22.10 and a total volume of 1,707.

UBA Urstadt Biddle Properties Inc Recent Headline News

NYSE stocks posting largest volume decreases
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — A look at the 10 biggest volume decliners on New York Stock Exchange at the close of trading:
MOG.B: 74.65 (-0.13), FRF: 9.94 (+0.13), MOG.A: 74.30 (-0.34), UBA: 22.10 (-0.15), ARL: 5.45 (unch), UBP: 18.65 (-0.01), SRT: 7.48 (-0.05), NTL: 22.84 (-0.44), MS: 35.76 (-0.12)

Urstadt Biddle Properties Inc. Announces Closing of Class A Common Stock Offering
Business Wire - Mon Nov 03, 3:15PM CST
Urstadt Biddle Properties Inc. (the "Company" (NYSE:UBA), a self-administered equity real estate investment trust, today announced the closing of its previously announced underwritten public offering of 2,500,000 shares of its Class A common stock, resulting in $52.05 million of proceeds to the Company before offering expenses.
DB: 30.13 (+0.13), UBA: 22.10 (-0.15), UBP: 18.65 (-0.01)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:15AM CDT

CAMT: 2.92 (-0.17), ORB: 25.36 (+0.54), UNIS: 3.05 (-0.61), ALLY: 22.71 (-0.07), FB: 74.48 (-0.52), AMCC: 6.33 (+0.01), INVN: 14.52 (-0.43), AKS: 6.35 (-0.28), NBG: 2.19 (-0.04), RFMD: 13.42 (+0.08), BLDP: 2.79 (unch), CARA: 8.60 (-0.15), GT: 25.26 (-0.07), HIVE: 4.54 (-0.10), MCGC: 3.67 (+0.01), IBIO: 1.15 (-0.08), BIOS: 5.71 (+0.12), UBA: 22.10 (-0.15), ARCP: 8.65 (+0.15), SNY: 47.07 (+0.88), STM: 6.91 (+0.03), X: 35.17 (-1.53)

Urstadt Biddle prices secondary; -5.3% premarket
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 7:55AM CDT

UBA: 22.10 (-0.15)

Urstadt Biddle Properties Inc. Announces Pricing of Class A Common Stock Offering
Business Wire - Wed Oct 29, 7:44AM CDT
Urstadt Biddle Properties Inc. (the "Company" (NYSE:UBA) today announced the pricing of its underwritten offering of 2,500,000 shares of its Class A common stock at a price to the public of $21.30 per share. The Company has granted the underwriter an option for 30 days to purchase up to an additional 375,000 shares of its Class A common stock. The offering was made pursuant to the Company's shelf registration statement and settlement is expected to occur on or about November 3, 2014. Deutsche Bank Securities Inc. is acting as sole book-running manager for the offering.
DB: 30.12 (+0.12), UBA: 22.10 (-0.15), UBP: 18.65 (-0.01)

Urstadt Biddle commences public offering of 2.5m class A common stock shares
M2 - Wed Oct 29, 3:36AM CDT
Urstadt Biddle Properties Inc (NYSE:UBA), a real estate investment trust, said on Wednesday that it is offering 2,500,000 shares of its class A common stock in a public offering, under its existing shelf registration statement filed with the US Securities and Exchange Commission.
UBA: 22.10 (-0.15), UBP: 18.65 (-0.01)

Urstadt Biddle selling stock to fund acuqisitions
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 4:06PM CDT

UBA: 22.10 (-0.15)

Urstadt Biddle Properties Inc. Announces Offering of 2,500,000 Shares of Class A Common Stock
Business Wire - Tue Oct 28, 3:15PM CDT
Urstadt Biddle Properties Inc. (the "Company" (NYSE:UBA), a self-administered equity real estate investment trust, announced today that it is offering 2,500,000 shares of its Class A common stock in a public offering. In connection with the offering, the Company intends to grant the underwriter an option for 30 days to purchase an additional 375,000 shares of its Class A common stock.
DB: 30.12 (+0.12), UBA: 22.10 (-0.15), UBP: 18.65 (-0.01)

Urstadt Biddle Issues 6.75% Preferred - No Thanks
Rubicon Associates - at Seeking Alpha - Fri Oct 24, 11:49AM CDT

UBA: 22.10 (-0.15)

Urstadt Biddle Properties Inc. Announces Redemption of 7.50% Series D Senior Cumulative Preferred Stock
Business Wire - Wed Oct 22, 5:34PM CDT
On October 22, 2014, Urstadt Biddle Properties Inc. ("UBP" (NYSE: UBPPRD), issued a notice of redemption to the registered holders of its 7.50% Series D Senior Cumulative Preferred Stock (the "Series D Preferred Stock". UBP will redeem all 2,450,000 outstanding shares of the Series D Preferred Stock on November 21, 2014, the redemption date. The Series D Preferred Stock will be redeemed at a redemption price of $25.00 per share, plus $0.109375 per share, the amount equal to all dividends accrued and unpaid on a share of the Series D Preferred Stock from November 1, 2014 through the redemption date. UBP previously declared a regular quarterly dividend on the Series D Preferred Stock of $0.46875 per share payable on October 31, 2014 to stockholders of record on October 17, 2014.
UBA: 22.10 (-0.15), UBP: 18.65 (-0.01)

Urstadt Biddle Properties Inc. Announces Pricing of Series G Preferred Stock Offering
Business Wire - Wed Oct 22, 7:32AM CDT
Urstadt Biddle Properties Inc. (NYSE: UBA) (the "Company", a self-administered equity real estate investment trust today announced that it has priced a public offering of 2,800,000 shares of its 6.75% Series G Cumulative Redeemable Preferred Stock, liquidation preference of $25.00 per share, for estimated net proceeds before expenses of approximately $67.8 million. The offering is subject to customary closing conditions and is expected to close on or about October 28, 2014.
UBA: 22.10 (-0.15), UBP: 18.65 (-0.01)

Urstadt Biddle Properties Inc. Announces Offering of Series G Preferred Stock
Business Wire - Tue Oct 21, 7:33AM CDT
Urstadt Biddle Properties Inc. (NYSE: UBA) (the "Company", a self-administered equity real estate investment trust today announced the commencement of a public offering of 2,450,000 shares of its Series G Cumulative Redeemable Preferred Stock. In connection with the offering, the Company intends to grant the underwriters an option for 30 days to purchase an additional 367,500 shares to cover overallotments, if any. BMO Capital Markets is the sole book-running manager for the offering. Deutsche Bank Securities and Stifel are acting as joint lead managers for the offering. J.J.B. Hilliard, W.L. Lyons, LLC, Wunderlich Securities and BNY Mellon Capital Markets, LLC are acting as co-managers for the offering.
DB: 30.12 (+0.12), UBA: 22.10 (-0.15), UBP: 18.65 (-0.01)

Dividend Contenders: 34 Increases Expected By December 31
David Fish - at Seeking Alpha - Sat Oct 18, 5:44PM CDT

CASS: 49.00 (-0.41), MATW: 46.29 (-0.26), SEIC: 39.41 (-0.07), SFG: 68.33 (+0.07), NKE: 94.85 (-0.11), NKSH: 31.68 (-0.24), MDU: 25.67 (-0.28), SJI: 58.15 (+0.17), AEL: 27.36 (-0.48), MSM: 83.68 (-0.13), UMBF: 59.84 (-0.16), AAN: 26.95 (+0.89), YORW: 21.87 (-0.16), SYK: 88.48 (+0.04), ECL: 112.64 (-0.09), AXS: 49.23 (+0.01), WHG: 64.00 (-0.54), JJSF: 103.30 (-0.68), AROW: 27.32 (-0.11), LECO: 74.10 (-0.01), BRO: 32.48 (-0.02), WABC: 50.14 (-0.05), UBA: 22.10 (-0.15), RGLD: 65.90 (+3.95), ANDE: 54.82 (+0.05), UTMD: 57.99 (-0.21), EIX: 63.11 (+0.03), LG: 51.12 (-0.19), PB: 60.40 (-0.28), VGR: 21.84 (-0.26)

Urstadt Biddle's subsidiary acquires 51% equity interest in JV and owner of shopping centre in New York for USD7.8m
M2 - Mon Oct 13, 8:51AM CDT
A real estate investment trust, Urstadt Biddle Properties Inc's (NYSE:UBA) (NYSE:UBP) wholly-owned subsidiary closed the purchase of a 51% equity interest in a joint venture (JV) that owns the McLean Plaza Shopping Center in Yonkers, Westchester County, New York, for an investment of USD7.8m, the company revealed on Friday.
UBA: 22.10 (-0.15), UBP: 18.65 (-0.01)

Urstadt Biddle Properties Inc. Announces Acquisition of a 51% Equity Interest in a Joint Venture That Owns the McLean Plaza Shopping Center in Yonkers, Westchester County, New York
Business Wire - Fri Oct 10, 3:24PM CDT
Urstadt Biddle Properties Inc. (NYSE: UBA and UBP) announced today that a wholly-owned subsidiary had completed the purchase of a 51% equity interest in a joint venture that owns the McLean Plaza Shopping Center in Yonkers, Westchester County, New York for an investment of $7.8 million. The purchase price was subject to the company assuming its share of a $2.78 million first mortgage payable that encumbers the shopping center. The loan bears interest at the rate of 4.0% per annum and matures in December 2014. The company purchased its 51% interest from an affiliate of The Great Atlantic & Pacific Tea Company (A&P), which is an existing tenant in the shopping center. In conjunction with the purchase, A&P modified its lease and extended the initial term until 2034. The remaining 49% of the joint venture continues to be owned by entities owned by the two real estate families that originally developed the shopping center with A&P. The Company funded the acquisition with available cash and a borrowing on its unsecured revolving credit facility. The shopping center is located on McLean Avenue, in Yonkers, New York at the intersection with the Major Deegan Expressway (Interstate 87). The shopping center was built in 1982 and contains 57,000 square feet of leasable space anchored by a 35,000 square foot A&P Supermarket. Other tenants in the shopping center include Duane Reade pharmacy (a subsidiary of Walgreen's), an E-Z Pass Service Center, Dunkin Donuts and Ridgewood Savings Bank. Over 500,000 people live within three miles of the shopping center.
UBA: 22.10 (-0.15), WAG: 67.36 (-0.42), UBP: 18.65 (-0.01)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

BASIS Bellevue Expands with New K-4 Campus

Updated Category News Views 89

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

Continue Reading
Smirnoff Launches Marvel Event with $12.99 Offer

Updated Category News Views 68

Smirnoff's Bold Move to Ride Marvel's Coattails Here we are, watching a vodka brand hitch its wagon to a Hollywood juggernaut. Smirnoff has announced a fan experience to toast Marvel Studios' "Avengers: Doomsday." Of course, this isn't just about clinking glasses; it's a marketing stunt dressed in superhero tights. The impressive part? They’re selling the razzmatazz for...

Continue Reading
Ameritas Hires Actuarial Veteran as VP in Strategic Move

Updated Category News Views 115

Shifting Gears at Ameritas: New VP Takes the Helm Well, chalk one up for Ameritas on this move. They've just brought on Ying Zhao as the new vice president of actuarial and financial strategy. It's a mouthful of a title, sure, but it's the role itself that's worth watching. Ameritas, for those not tracking, is a major player in the insurance and financial universe, doing...

Continue Reading
Amgen Q3 2026 Results: What Investors Should Know

Updated Category News Views 93

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Continue Reading
Royce Global Trust: Insights on RGT's Performance

Updated Category News Views 80

Analyzing Royce Global Trust's Approach When you dig into the Royce Global Trust portfolio, what emerges is a tapestry woven through decades of grit and determination in the investing world. This closed-end fund, trading under the symbol NYSE: RGT, is no stranger to the ebbs and flows of global markets. With every tick of the clock, speculation dances around this fund's...

Continue Reading
transcosmos: Not Just Calls—Evolving Business Strategy

Updated Category News Views 110

Turning Talk into Triumphs Award chatter isn't exactly rare in this industry, but the latest accolades rolling in for transcosmos from the Best Contact Center Indonesia 2026 ain't your run-of-the-mill pat on the back. Sure, a trophy's a trophy, but when they snatch Gold in the Business Contribution category and another shiny Silver in People Development, it’s hinting at...

Continue Reading
Bloomberg Law Awards Series Celebrates Legal Excellence

Updated Category News Views 54

New Awards Shine Light on Corporate Legal Teams Here's one for the books: Bloomberg Law is rolling out a shiny new awards program called Inside In-House: Legal Departments of the Year. Now, this isn't some vanity affair because it's aimed at celebrating the folks in legal teams who make companies tick behind the scenes. Openings for nominations run through November 20,...

Continue Reading
Oracle's Bold Vision: Targeting $225B Revenue by 2030

Updated Category News Views 132

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Continue Reading
BD's New Liverty™ TIPS Stent: A Game Changer?

Updated Category News Views 75

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

Continue Reading
Ascletis' ASC30 Achieves Significant HbA1c Reductions

Updated Category News Views 73

When you dive into the world of biopharma, you never quite know what's going to grab your attention next. Today, it's Ascletis Pharma's (HKEX: 1672) GLP-1 receptor agonist, ASC30, that's piqued my interest. It just wrapped up a U.S. Phase II study with a bang, showing off with some impressive results for type 2 diabetes treatment. This ain't no half-hearted...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Assistant by ClickBid Revolutionizes Fundraising

Updated Category News Views 155

ClickBid Introduces Groundbreaking AI Assistant ClickBid, recognized as a pioneer in event fundraising technology, proudly presents ClickBid Search. This is the first custom GPT-powered AI assistant tailored specifically for nonprofits, designed to offer immediate and relevant answers to help organizations optimize their event strategies. Available at no cost to all...

Continue Reading
TIER IV and TUM Drive Level 4 Autonomous Cars

Updated Category News Views 25

Autonomous Driving Gets a German Boost Well folks, looks like the autonomous vehicle scene is hitting the autobahns with more horsepower than ever before. Today’s chatter is all about how TIER IV and the Technical University of Munich (TUM) have teamed up, tapping into the grid as they ride the waves of cutting-edge NVIDIA tech. The Sparks Under the Hood: NVIDIA...

Continue Reading
Vericel Corporation's Upcoming Presentation at MedTech Conference

Updated Category News Views 147

Vericel Corporation's Engagement at the MedTech Conference CAMBRIDGE, Mass. — Vericel Corporation (NASDAQ:VCEL), a recognized leader in advanced therapies for sports medicine and severe burn care, has exciting news regarding its participation at the upcoming Truist Securities MedTech Conference. The company will be featured in a fireside chat, slated to take place at...

Continue Reading
Gildan Achieves Strong Q2 Results: Revenue and Finances Surge

Updated Category News Views 128

Gildan Reports Remarkable Growth in Second Quarter Earnings Gildan Activewear Inc. (NYSE: GIL, TSX: GIL) has achieved record net sales of $919 million during the second quarter, reflecting a strong 6.5% increase compared to the previous year. Strong Operational Performance and Profitability This quarter's operating margin stood at an impressive 21.7%, with an adjusted...

Continue Reading
MimiVax and UI Pharmaceuticals Mark Key Production Milestone

Updated Category News Views 260

MimiVax and UI Pharmaceuticals Mark Key Production Milestone MimiVax and UI Pharmaceuticals have achieved an exciting development in the field of cancer treatment with the clinical manufacture of SurVaxM, an innovative immunotherapeutic vaccine aimed at targeting glioblastoma. SurVaxM proudly stands out as the first product to be manufactured at UI Pharmaceuticals' newly...

Continue Reading